Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?

Abstract

LINKED CONTENTThis article is linked to Verstockt et al papers. To view these articles, visit https://doi.org/10.1111/apt.16955

Translational, Precision, and Personalized Medicine in Gastroenterology

“…Currently, only one molecule is approved for clinical use, but several other molecules in the same class are close to market and may prove useful in the treatment of Crohn’s disease. Their particular properties (they are small molecules that are rapidly bioavailable, have a short duration of action, and are unlikely to trigger the mechanism of immune tolerance that occurs with other biologic drugs) and their ability to determine response by examining the phosphorylation of their target (STAT3) at the nuclear level, facilitating a rapid decrease in levels of IL-4, or identifying the hub gene make them promising candidates for personalized therapy in patients with ulcerative colitis [ 12 , 13 ].…”